They make good canon fodder when forced to compete against sound logic and incontrovertible evidence. I sometime pray for their souls.
Is that all that you've got? You obviously can't read, can you.
Are you even a member at iHub? Let's see what you post of substance. We haven't seen anything from you. Surprise us with something profound. We're waiting. LOL
Cry me a river and I'll sell you a bridge.
Tell us what you know about ONCS. What you like. What you don't like. I'll answer any questions you may have.
I promise I will respond in a fair and balanced way. And I don't work for FOX.
Son, I beg to differ.
I speak either down or up to the intelligence of the poster.
You reap what you sow and this is the response you are getting from me for your post.
What would you like to know about ONCS? I'll answer your questions.
Cry us a river and we'll sell you a bridge. LOL LOL
We see that you're starting to spell better. That's at least some progress.
Very well said. iHub is DEAD.
Come join us for sane discussions at the ONCS group at Google.
Dr. Pierce didn't come to ONCS without good reason. They will ultimately carve out an attractive piece of the huge combinatorial immunological oncology space.
Up, up, and away!
Provide clinical proof of efficacy with links, please.
Otherwise, your grammar speaks for itself.
He's obviously not a doctor.
The dude has no credibility nor background in this field.
And anyone with an education can respond with more than just single word sentences. He's a pathetic joke who is working very hard for pennies.
He was a Fulbright Award recipient. He studied Philosophy at the Albert-Ludwigs-University in Freiburg, Germany. He is a graduate of Yale College and Brown University School of Medicine. Dr. Pierce received his Post-Doctoral Training at the University of Washington, Seattle, WA. He trained at Brown University School of Medicine in Providence, RI, and received an Undergraduate Education at Yale University in New Haven, CT.
Yes, I think we have a pretty good pedigree here.
Dr. Robert Hamilton Pierce M.D. has been the Chief Scientific Officer and Global Head of R&D at OncoSec Medical Incorporated since September 16, 2014. Dr. Pierce served as the Chief Medical Officer of OncoSec Medical Incorporated since December 12, 2013 until September 16, 2014.
Dr. Pierce served at Merck Research Labs -- Palo Alto where he spent almost seven years in leading a 20--person team, dedicated to developing disease-oriented and tissue-based translational medicine platforms. From 2001 to 2007, he served several leadership positions at the University of Rochester School of Medicine, including Director of the Autopsy Service at Strong Memorial Hospital.
Dr. Pierce was responsible for contributions to multiple successful IND applications, including critical biomarker development programs such as the anti-PD-L1 immunohistochemistry assay supporting Merck's MK-3475 trials. He was instrumental in designing two Phase 2 anti-PD-1 (MK-3475) oncology studies. He also focused on immunomodulatory receptor (IMR) programs. He served as a Discovery Project Team Leader for two novel drug candidates.
He served as an Executive Director of Merck Research Labs. He practiced as a staff pathologist to develop the graduate curriculum in pathomechamism of disease. He was the principal investigator of a RO1-funded research lab, Dr. Pierce played an important role in the university's clinical and academic research programs.
He is the co-author of over fifty peer-reviewed journal articles and book chapters, and is a reviewer for numerous scientific journals as well as National Institute of Health grants. Dr. Pierce is well regarded for his career-long research into mechanisms of immune tolerance and has drug development experience. He is a key Member of the global development team behind Merck's FDA-designated "breakthrough" anti-PD-1 program (MK-3475).
Admit it. You've lost.
You got rid of 32 very smart people and the Google board gained 225 members in the same time period.
The more you post here the more you become exposed for who you really are.
We're now up to 225 members at the Google site and growing. Judging on the size of the investments there, we probably represent at least 15-20% of the float.